IRLA IRulya Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662774 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY193.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-98.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets26.6%
Debt / equity—
Current ratio14.72x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.44x
Accruals ratio-55.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.85M | $5.46M | $6.84M | $12.60M | $8.08M | $6.55M | $8.14M | $5.83M |
| SG&A expense | $9.02M | $16.63M | $4.27M | $3.63M | $3.28M | $3.34M | $4.79M | $4.28M |
| Operating income | -$13.14M | -$79.78M | -$14.59M | -$19.35M | -$13.43M | -$10.43M | -$14.86M | -$12.01M |
| Pretax income | — | — | — | — | — | — | -$14.98M | — |
| Income tax | -$302,000 | $75,000 | -$5.34M | $3.15M | -$46,000 | $67,000 | $47,000 | $7,000 |
| Net income | -$27.74M | -$75.49M | $35.91M | -$39.46M | -$13.44M | -$16.05M | -$15.03M | -$12.46M |
| EBITDA | -$13.13M | -$79.74M | -$14.55M | -$19.31M | -$13.39M | -$10.39M | -$14.83M | -$12.00M |
| EPS (basic) | -2.31 | -12.31 | 3.60 | — | -49.83 | -68.75 | -3.42 | — |
| EPS (diluted) | -2.31 | -12.31 | 2.88 | — | -49.83 | -68.75 | -3.42 | — |
| Weighted avg. shares (diluted) | 12.00M | 6.13M | 9.19M | — | 269,757 | 233,431 | 4.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $39.82M | $115.98M | $18.16M | $5.81M | $6.45M | $16.83M | $7.77M | $6.21M |
| Short-term investments | $65.42M | $0 | $0 | $11.94M | — | — | — | $34.57M |
| Current assets | $106.30M | $123.41M | $25.58M | $22.90M | $29.20M | $37.34M | $33.83M | $44.04M |
| PP&E, net | $69,000 | $506,000 | $550,000 | $595,000 | $616,000 | $573,000 | $448,000 | $315,000 |
| Goodwill | — | — | — | — | $0 | — | — | $0 |
| Intangibles | $0 | $0 | $0 | $67.82M | $67.73M | $67.57M | $62.37M | $60.05M |
| Total assets | $106.47M | $124.00M | $26.62M | $93.52M | $109.90M | $117.21M | $107.09M | $114.48M |
| Current liabilities | $7.22M | $8.50M | $8.77M | $43.23M | $26.04M | $7.47M | $8.36M | $7.28M |
| Short-term debt | $0 | $0 | $0 | $18.03M | $17.52M | — | — | $0 |
| Long-term debt | — | — | — | $0 | $0 | $16.99M | $15.27M | $14.32M |
| Total debt | — | — | — | $18.03M | $17.52M | $16.99M | $15.27M | $14.32M |
| Total liabilities | $28.37M | $15.51M | $10.95M | $129.24M | $108.84M | $105.47M | $88.51M | $84.33M |
| Shareholders' equity | -$65.70M | -$35.32M | $15.67M | -$35.71M | $1.06M | $11.74M | $18.58M | $30.15M |
| Net debt | — | — | — | $12.22M | $11.07M | $163,000 | $7.50M | $8.11M |
| Shares outstanding | 1.02M | 1.02M | 13.79M | 278,627 | 54.49M | 53.62M | 44.09M | 44.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.84M | -$18.89M | -$7.63M | -$10.48M | -$9.93M | -$11.41M | -$9.60M | -$7.55M |
| Capital expenditure | $71,000 | $0 | $0 | $4,000 | $74,000 | $126,000 | $148,000 | $133,000 |
| Free cash flow | -$9.91M | -$18.89M | -$7.63M | -$10.48M | -$10.00M | -$11.54M | -$9.75M | -$7.68M |
| Investing cash flow | -$67.79M | $8.00M | $12.00M | $8.07M | -$1.78M | $6.04M | $10.90M | $10.87M |
| Financing cash flow | -$10,000 | $108.93M | $9.44M | $2.03M | $1.38M | $14.41M | $87,000 | $0 |
| Depreciation & amortization | $15,000 | $41,000 | $36,000 | $39,000 | $36,000 | $35,000 | $32,000 | $16,000 |
| Stock-based compensation | $1.64M | $12.09M | $1.29M | $1.19M | $1.25M | $1.27M | $1.39M | $1.12M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.